Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Benzinga Newsdesk www.benzinga.com Negative 88.9%

Neg 88.9% Neu 0% Pos 0%

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.

Comments

No comments yet. Be the first!